Barclays Maintains Overweight on Ligand Pharmaceuticals, Raises Price Target to $350
Benzinga Newsdesk 8 hours ago
Analyst RatingsNewsPrice Target
Barclays analyst Glen Santangelo maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight and raises the price target from $345 to $350.
Barclays analyst Glen Santangelo maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight and raises the price target from $345 to $350.